Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

RLMD vs PLUR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RLMD Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

RLMD Overall Winner 6-Pillar Tally: RLMD 4 – 1 PLUR (1 Tie) Matrix Metrics: RLMD 5 – 4 PLUR

As of Nov 17, 2026, Relmada Therapeutics, Inc. (RLMD) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RLMD carries a Unified Composite Score of 39.0/100 (SELL) at $3.00 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin).

  • Defensive Composite Rating Caution: Although RLMD compares more favorably head-to-head, both RLMD (39.0/100 SELL) and PLUR (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: RLMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.2); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RLMD vs PLUR
RLMD NASDAQ Head-to-Head Winner
Relmada Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.00
-16.76% 1D
Market Cap $449.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.69β · 107% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 15.0 Fund 38.0 Flow 68.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.4%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $3.72 · SMA50: $3.73
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (RLMD 4 – 1 PLUR)

Columns: Metric · RLMD · PLUR
1. Valuation Multiples PLUR
Forward P/E N/M 3.6x
Trailing P/E N/M 3.6x
PEG Ratio N/M N/M
EV / Revenue N/M 44.6x
2. Growth & Scale RLMD
Revenue Growth (YoY) +0.0% -15.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.0M
Market Cap $449.2M $15.1M
3. Profitability & Quality RLMD
Gross Margin N/A 44.6%
Operating Margin 0.0% -2454.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -64.7% -1022.0%
4. Balance Sheet & Cash Flow RLMD
Cash Generation (TTM) -$46M -$22M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.82 Book/Sh · -64.7% ROE $30M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RLMD
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 93.2% (36th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RLMD (5) vs PLUR (4)
Institutional Metric RLMD PLUR Criterion Row Edge
Market Capitalization
Scale
$449.2M $15.1M Larger Scale RLMD
Trailing P/E Ratio
Valuation
N/M 3.6x Lower Multiple PLUR
Forward P/E Ratio
Valuation
N/M 3.6x Lower Multiple PLUR
Revenue Growth (YoY)
Growth
+0.0% -15.8% Higher Growth RLMD
Operating Margin (TTM)
Profitability
0.0% -2454.5% Higher Margin RLMD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-64.7% -1022.0% Higher ROE RLMD
52-Week Range Position
Momentum
0% ($3–$8) 2% ($1–$5) Stronger Trend PLUR
Beta / 30D Volatility
Risk Regime
1.69β · 107% Vol 0.80β · 102% Vol Lower Realized Risk PLUR
Unified Institutional Score
Composite Signal
39.0 / 100 (SELL) 28.8 / 100 (SELL) Higher Composite RLMD
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 44.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$46M ($1.82 Book/Sh · -64.7% ROE) -$22M ($30M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUR +16.0 pp
RLMD: -4.91% · PLUR: +11.09%
3M Horizon RLMD +8.56 pp
RLMD: -37.78% · PLUR: -46.34%
6M Horizon RLMD +5.27 pp
RLMD: -57.25% · PLUR: -62.52%
1Y Horizon RLMD +51.61 pp
RLMD: -23.92% · PLUR: -75.53%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RLMD Revenue PLUR Revenue RLMD Op. Margin PLUR Op. Margin Margin Leader
FY2018 N/A $0M N/A -67462.0% PLUR
FY2019 N/A $0M N/A -65800.0% PLUR
FY2020 N/A $0M N/A -128156.5% PLUR
FY2022 N/A $0M N/A -17774.8% PLUR
FY2023 N/A $0M N/A -9493.4% PLUR
FY2024 N/A $0M N/A -6796.9% PLUR
FY2025 N/A $0M N/A -1659.9% PLUR
FY2026 N/A $0M N/A -2454.5% PLUR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RLMD BREAKDOWN
135d in phase · OBV ACCUMULATION
Current IV 93.2%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RLMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RLMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RLMD vs PLUR Key Questions & Quantitative Answers

As of Nov 17, 2026, Relmada Therapeutics, Inc. (RLMD) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RLMD carries a Unified Composite Score of 39.0/100 (SELL) at $3.00 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin). Defensive Composite Rating Caution: Although RLMD compares more favorably head-to-head, both RLMD (39.0/100 SELL) and PLUR (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: RLMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.2); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RLMD leads the Growth & Scale pillar: RLMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PLUR at -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), RLMD cumulative revenue shifted N/A while PLUR shifted N/A. In operating R&D and SG&A reinvestment, RLMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLUR.

PLUR screens cheaper on headline valuation multiples. RLMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RLMD (-64.7% ROE) versus PLUR (-1022.0% ROE) capital efficiency.

In options market volatility and institutional positioning, RLMD carries 93.2% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 107% Vol realized risk). By comparison, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.